Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 12/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547491 | 0.87 | MAPT (0.51) | DGAT1KCNH2MAPTKIF11 | |
| SCHEMBL22907251 | 0.87 | MAPT (0.51) | DGAT1KCNH2MAPTKIF11 | |
| SCHEMBL20120342 | 0.87 | MAPT (0.51) | DGAT1KCNH2MAPTKIF11 | |
| SCHEMBL20120343 | 0.87 | MAPT (0.51) | DGAT1KCNH2MAPTKIF11 | |
| SCHEMBL20129171 | 0.84 | MAPT (0.48) | DGAT1KCNH2MAPTKIF11 | |
| SCHEMBL20129172 | 0.84 | MAPT (0.48) | DGAT1KCNH2MAPTKIF11 | |
| SCHEMBL20233712 | 0.84 | MAPT (0.50) | MAPTKIF11 | |
| SCHEMBL20133146 | 0.83 | MAPT (0.53) | KCNH2MAPTKIF11 | |
| SCHEMBL20133244 | 0.82 | MAPT (0.47) | MAPTKIF11 | |
| SCHEMBL20120468 | 0.81 | DGAT1 (0.44) | DGAT1KCNH2MAPTSOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | DGAT1 4519/4885KCNH2 4870/4885MAPT 1/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | DGAT1 4651/4885KCNH2 4854/4885MAPT 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.